Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Gerber

Showing results (191-200 of 289) with videos related to

Pageof 29
Sort By:
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLCDavid E Gerber, Paul Swanson, Ariel Lopez-Chavez, et al.
Vaccine|July 13, 2025
SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient populationBenjamin M Greenberg, John D Minna, David E Gerber, et al.
Oncoimmunology|May 13, 2024
Distinct autoantibody profiles across checkpoint inhibitor types and toxicitiesHong Mu-Mosley, Mitchell S von Itzstein, Farjana Fattah, et al.
Cancer Medicine|June 8, 2022
Survival of cancer survivors with a new pancreatic cancer diagnosisSandi L Pruitt, Anna Tavakkoli, Hong Zhu, et al.
Journal for Immunotherapy of Cancer|May 30, 2024
Use of artificial intelligence chatbots in clinical management of immune-related adverse eventsHannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work GroupAlexander I Spira, Mark D Stewart, Suzanne Jones, et al.
Cancer Informatics|May 7, 2019
Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung CancerTao Wang, Rong Lu, Sunny Lai, et al.
Lung Cancer (Amsterdam, Netherlands)|July 9, 2023
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancerSheena Bhalla, Farjana J Fattah, Chul Ahn, et al.
JAMA Oncology|October 4, 2017
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical TrialPuneeth Iyengar, Zabi Wardak, David E Gerber, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 10, 2015
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenograftsDavid E Gerber, Guiyang Hao, Linda Watkins, et al.
Pageof 29

Showing results (191-200 of 289) with videos related to

Sort By:
Pageof 29
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLCDavid E Gerber, Paul Swanson, Ariel Lopez-Chavez, et al.
Vaccine|July 13, 2025
SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient populationBenjamin M Greenberg, John D Minna, David E Gerber, et al.
Oncoimmunology|May 13, 2024
Distinct autoantibody profiles across checkpoint inhibitor types and toxicitiesHong Mu-Mosley, Mitchell S von Itzstein, Farjana Fattah, et al.
Cancer Medicine|June 8, 2022
Survival of cancer survivors with a new pancreatic cancer diagnosisSandi L Pruitt, Anna Tavakkoli, Hong Zhu, et al.
Journal for Immunotherapy of Cancer|May 30, 2024
Use of artificial intelligence chatbots in clinical management of immune-related adverse eventsHannah Burnette, Aliyah Pabani, Mitchell S von Itzstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work GroupAlexander I Spira, Mark D Stewart, Suzanne Jones, et al.
Cancer Informatics|May 7, 2019
Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung CancerTao Wang, Rong Lu, Sunny Lai, et al.
Lung Cancer (Amsterdam, Netherlands)|July 9, 2023
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancerSheena Bhalla, Farjana J Fattah, Chul Ahn, et al.
JAMA Oncology|October 4, 2017
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical TrialPuneeth Iyengar, Zabi Wardak, David E Gerber, et al.
American Journal of Nuclear Medicine and Molecular Imaging|November 10, 2015
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenograftsDavid E Gerber, Guiyang Hao, Linda Watkins, et al.
Pageof 29